Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non-acral nevus-associated melanoma in situ: An institutional experience and meta-analysis

IF 1.6 4区医学 Q3 DERMATOLOGY

Journal of Cutaneous Pathology Pub Date : 2024-06-21 DOI:10.1111/cup.14671

Chau M. Bui MD, Huy Gia Vuong MD, PhD, Minh-Khang Le MD, Josephine D'Angelo MD, Kathleen Mannava MD, Bruce R. Smoller MD

{"title":"Clinical implication of PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non-acral nevus-associated melanoma in situ: An institutional experience and meta-analysis","authors":"Chau M. Bui MD, Huy Gia Vuong MD, PhD, Minh-Khang Le MD, Josephine D'Angelo MD, Kathleen Mannava MD, Bruce R. Smoller MD","doi":"10.1111/cup.14671","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>PReferentially expressed Antigen in MElanoma (PRAME) has shown utility in differentiating benign from malignant melanocytic neoplasms. In this study, we investigated the clinical significance of PRAME expression in dysplastic nevi (DN) and nevus-associated melanoma in situ (MIS).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We included 172 DN and 38 nevus-associated MIS from our institutional archive. PRAME positive expression was defined as nuclear staining in at least 75% of melanocytes. In addition, relevant studies from PubMed and Web of Science were incorporated into a meta-analysis using the random-effects model to assess PRAME expression in MIS and DN.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Our institutional data revealed that 71.1% of nevus-associated MIS cases exhibited positive PRAME expression in the MIS components, whereas all DN components were negative for PRAME. 5.7% of cases diagnosed as DN in our cohort demonstrated diffuse positivity for PRAME. Notably, MIS associated with DN displaying epidermal and dermal components displayed a higher likelihood of PRAME positivity compared to those arising on a background of DN with solely epidermal (junctional) components (84% vs. 46%, <i>p</i> = 0.024). The meta-analysis indicated that the pooled PRAME positivity in MIS and DN was 54.5% and 1.9%, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>PRAME is a valuable immunohistochemical marker for differentiating MIS from DN, particularly in the context of nevus-associated MIS.</p>\n </section>\n </div>","PeriodicalId":15407,"journal":{"name":"Journal of Cutaneous Pathology","volume":"51 10","pages":"783-789"},"PeriodicalIF":1.6000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Pathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cup.14671","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

PReferentially expressed Antigen in MElanoma (PRAME) has shown utility in differentiating benign from malignant melanocytic neoplasms. In this study, we investigated the clinical significance of PRAME expression in dysplastic nevi (DN) and nevus-associated melanoma in situ (MIS).

Methods

We included 172 DN and 38 nevus-associated MIS from our institutional archive. PRAME positive expression was defined as nuclear staining in at least 75% of melanocytes. In addition, relevant studies from PubMed and Web of Science were incorporated into a meta-analysis using the random-effects model to assess PRAME expression in MIS and DN.

Results

Our institutional data revealed that 71.1% of nevus-associated MIS cases exhibited positive PRAME expression in the MIS components, whereas all DN components were negative for PRAME. 5.7% of cases diagnosed as DN in our cohort demonstrated diffuse positivity for PRAME. Notably, MIS associated with DN displaying epidermal and dermal components displayed a higher likelihood of PRAME positivity compared to those arising on a background of DN with solely epidermal (junctional) components (84% vs. 46%, p = 0.024). The meta-analysis indicated that the pooled PRAME positivity in MIS and DN was 54.5% and 1.9%, respectively.

Conclusion

PRAME is a valuable immunohistochemical marker for differentiating MIS from DN, particularly in the context of nevus-associated MIS.

查看原文本刊更多论文

PRAME 免疫组化在区分非痤疮相关原位黑色素瘤和发育不良痣中的临床意义：机构经验和荟萃分析

引言黑色素瘤中的干扰性表达抗原（PRAME）在区分良性和恶性黑色素细胞瘤方面具有一定的作用。在这项研究中，我们调查了PRAME在发育不良痣（DN）和痣相关原位黑色素瘤（MIS）中表达的临床意义。PRAME阳性表达的定义是至少75%的黑色素细胞核染色。此外，我们还将PubMed和Web of Science上的相关研究纳入荟萃分析，使用随机效应模型评估PRAME在MIS和DN中的表达。结果我们的机构数据显示，71.1%的痣相关MIS病例在MIS成分中显示PRAME阳性表达，而所有DN成分的PRAME均为阴性。我们队列中 5.7% 诊断为 DN 的病例显示 PRAME 呈弥漫性阳性。值得注意的是，与那些仅有表皮（交界处）成分的 DN 相关的 MIS 显示出 PRAME 阳性的可能性更高（84% 对 46%，P = 0.024），而与那些显示出表皮和真皮成分的 DN 相关的 MIS 显示出 PRAME 阳性的可能性更高。荟萃分析表明，MIS 和 DN 中汇总的 PRAME 阳性率分别为 54.5% 和 1.9%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cutaneous Pathology 医学-病理学

CiteScore

3.20

自引率

5.90%

发文量

174

审稿时长

3-8 weeks

期刊介绍： Journal of Cutaneous Pathology publishes manuscripts broadly relevant to diseases of the skin and mucosae, with the aims of advancing scientific knowledge regarding dermatopathology and enhancing the communication between clinical practitioners and research scientists. Original scientific manuscripts on diagnostic and experimental cutaneous pathology are especially desirable. Timely, pertinent review articles also will be given high priority. Manuscripts based on light, fluorescence, and electron microscopy, histochemistry, immunology, molecular biology, and genetics, as well as allied sciences, are all welcome, provided their principal focus is on cutaneous pathology. Publication time will be kept as short as possible, ensuring that articles will be quickly available to all interested in this speciality.